Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.29 USD | -0.29% | -3.29% | -8.12% |
Apr. 11 | Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target | MT |
Mar. 22 | B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating | MT |
Financials (USD)
Sales 2024 * | 185M | Sales 2025 * | 251M | Capitalization | 364M |
---|---|---|---|---|---|
Net income 2024 * | -12M | Net income 2025 * | 23M | EV / Sales 2024 * | 1.97 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.45 x |
P/E ratio 2024 * |
-31.9
x | P/E ratio 2025 * |
17.3
x | Employees | 315 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.42% |
Latest transcript on Harrow, Inc.
1 day | -0.29% | ||
1 week | -3.29% | ||
Current month | +0.98% | ||
1 month | -22.10% | ||
3 months | -4.72% | ||
6 months | -19.73% | ||
Current year | -8.12% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Baum
CEO | Chief Executive Officer | 51 | 05-12-31 |
Andrew Boll
DFI | Director of Finance/CFO | 41 | 11-11-30 |
Jamie Webb
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Baum
CEO | Chief Executive Officer | 51 | 05-12-31 |
Director/Board Member | 65 | Jan. 25 | |
Adrienne Graves
BRD | Director/Board Member | 69 | Jan. 25 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 0 M€ | +3.48% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 10.29 | -0.29% | 226,924 |
24-05-08 | 10.32 | -5.67% | 267,782 |
24-05-07 | 10.94 | +4.29% | 262,710 |
24-05-06 | 10.49 | +1.06% | 194,654 |
24-05-03 | 10.38 | -2.44% | 280,144 |
Delayed Quote OTC Markets, May 09, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.12% | 364M | |
+32.36% | 695B | |
+26.51% | 568B | |
-4.40% | 361B | |
+19.46% | 330B | |
+3.50% | 283B | |
+16.57% | 239B | |
+8.28% | 204B | |
-7.61% | 198B | |
+8.62% | 168B |
- Stock Market
- Equities
- HROW Stock